Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	16.74	8.78	12.41	-	-	-
Revenue Growth (YoY)	81.08%	-29.22%	-	-	-	-
Gross Profit	16.74	8.78	12.41	-	-	-
Selling, General & Admin	46.56	41.32	38.92	31.9	20.85	11.91
Research & Development	87.49	82.23	77.84	54.17	32.2	23.76
Operating Expenses	134.05	123.55	116.76	86.07	53.04	35.68
Operating Income	-117.31	-114.77	-104.36	-86.07	-53.04	-35.68
Interest & Investment Income	12.26	9.91	3.12	0.12	0.7	3.35
Other Non Operating Income (Expenses)	-0.41	0.17	0.17	0.14	0.1	0
Pretax Income	-105.46	-104.7	-101.07	-85.81	-52.24	-32.33
Net Income	-105.46	-104.7	-101.07	-85.81	-52.24	-32.33
Net Income to Common	-105.46	-104.7	-101.07	-85.81	-52.24	-32.33
Shares Outstanding (Basic)	51	44	39	37	33	18
Shares Outstanding (Diluted)	51	44	39	37	33	18
Shares Change (YoY)	19.65%	13.10%	5.87%	9.71%	86.34%	2433.56%
EPS (Basic)	-2.07	-2.38	-2.60	-2.34	-1.56	-1.80
EPS (Diluted)	-2.07	-2.38	-2.60	-2.34	-1.56	-1.80
Free Cash Flow	-84.7	-82.68	-35.83	-68.11	-43.27	-32.69
Free Cash Flow Per Share	-1.66	-1.88	-0.92	-1.85	-1.29	-1.82
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-700.62%	-1307.21%	-841.24%	-	-	-
Profit Margin	-629.86%	-1192.47%	-814.73%	-	-	-
Free Cash Flow Margin	-505.87%	-941.72%	-288.82%	-	-	-
EBITDA	-115.03	-112.3	-102.81	-85.09	-52.16	-35.23
D&A For EBITDA	2.28	2.47	1.55	0.97	0.89	0.45
EBIT	-117.31	-114.77	-104.36	-86.07	-53.04	-35.68

Source: S&P Capital IQ. Standard template. Financial Sources.